[ Partner Login ]

 

 

Work Packages:

WP1: Patient registry and biobank.

WP-leader: Eystein Husebye (P1)
The main work for this WP is to establish a network of European patient registries and biobanks on autoimmune Addison’s disease (AAD) containing sera, DNA and RNA. Collection of a European database and biobank will be a central resource for the other work packages; the patients will be invited to participate in treatment studies and blood samples will be used in the work packages on genetics and immunology.

WP2: Natural course of autoimmune Addison’s disease

WP-leader: Anna-Lena Hulting (P9)
The aim is to describe the natural course of the disease, estimate prevalence and incidence in selected regions of Europe, measure quality of life in patients and controls.

 

WP3: Dog models of Addison’s disease

WP-leader: Olle Kämpe (P2)
The main work will be to find genes involved in pathogenesis of Addison’s disease in dog; and study the same genes in human.

 

WP4: Mouse models of Addison’s disease

WP-leader Georg Holländer (P11)

The main work in WP 4 is to establish a mouse model of Addison’s disease by targeted deletion of 21-hydroxylase in the thymus and monitor for occurrence of autoimmunity.

WP5: Genetics in humans

WP-leader: Simon Pearce (P4)
The aim is to provide robust replication of genetic associations at genes known or suspected to be associated with AAD and other organ-specific autoimmune diseases exploiting the power provided by a large patient registry. Determine the contribution of novel common and rare variant alleles to AAD susceptibility using a combination of genome-wide association analysis and targeted sequencing of leukocyte cDNA using novel high-throughput sequencing technologies. Validate any findings from canine genomics in human AAD and healthy control subjects. Identify novel biochemical pathways that are implicated in AAD and other autoimmune conditions that may be novel drug targets.

WP6: Immune Regulation

WP-leader: Klaus Badenhoop (P6)
The main work in WP6 is to characterize the mechanism for T cell mediated destruction of the adrenal cortex, identify surrogate screening markers for preclinical AAD, identify mechanisms for loss of tolerance to adrenal antigens and characterise pathways and epitopes that can be used to modulate cellular and humoral immunity in order to prevent immune mediated adrenal and other organ destruction in the long term.

WP7: Diagnosis, treatment and follow-up

WP-leader: Alberto Falorni (P8)
The main work will be to implement treatment-sensitive and Addison-specific quality of life questionnaire, improve therapy with more physiological dosing of glucocorticoids, optimizing testing of pre-clinical adrenal dysfunction and testing therapies in pre-clinical adrenal insufficiency.

WP8: Dissemination of knowledge

WP-leader: Eystein Husebye (P1)
The first work will be to make a web-site for patients, health professionals and the public and formulate a European consensus statement on diagnosis treatment and follow-up.
The main aim of this WP is to develop a detailed plan for the use and dissemination of knowledge generated during the project and beyond. The plan will also include a plan for commercial exploitation of the results generated by Euradrenal.

WP9: Project Management

WP-leader: Eystein Husebye (P1)
The main work is to run the project according to time table and management plan and to ensure that allocated funds are spent in the most cost-effective way and reports to the EU.